GlassScriptPhysician profile
Julie Ann Ball
NPI 1881395499
$1,635.35
in general payments reported to CMS, 2019-2025
33 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $477 · 2024: $904 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.36 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $164.34 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $139.20 | 2023-2024 | |
| Astellas Pharma US INC | $129.17 | 2024-2025 | Vyloy |
| Celgene Corporation | $106.52 | 2023-2024 | Pomalyst, Reblozyl |
| Gilead Sciences, INC. | $102.60 | 2024 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $102.07 | 2023-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Amgen INC. | $101.19 | 2023 | Kyprolis, Xgeva, Nplate |
| Pfizer INC. | $80.94 | 2023-2025 | |
| Novocure INC. | $62.42 | 2024 | Optune Lua (Novottf-200t) |
| Merck Sharp & Dohme LLC | $60.26 | 2024-2025 | Keytruda |
| Lilly USA, LLC | $51.09 | 2023-2024 | Jaypirca, Retevmo, Verzenio |
| Stemline Therapeutics INC. | $50.31 | 2023-2025 | Orserdu |
| Genzyme Corporation | $45.48 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $43.30 | 2024 | Calquence, Lynparza |
| Genentech USA, INC. | $38.77 | 2024-2025 | Venclexta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $31.26 | 2023-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $26.83 | 2024 | Ultomiris |
| Sumitomo Pharma America, INC. | $26.09 | 2025 | Orgovyx |
| Genmab U.S., INC. | $23.58 | 2023 | Epkinly |
| Taiho Oncology, INC. | $22.36 | 2024 | |
| Beigene USA, INC. | $22.01 | 2024 | Brukinsa |
| Geron Corporation | $21.50 | 2024 | Rytelo |
| Tempus Ai, INC | $20.90 | 2024 | Xt Cdx |
| Regeneron Healthcare Solutions, INC. | $18.02 | 2025 | Libtayo |
| Puma Biotechnology, INC. | $18.01 | 2024 | |
| Foundation Medicine, INC. | $17.26 | 2023 | |
| Seagen INC. | $16.77 | 2023 | Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $16.60 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $16.30 | 2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $16.10 | 2024 | |
| Adaptive Biotechnologies Corporation | $15.83 | 2024 | Clonoseq |
| Abbvie INC. | $14.34 | 2024 | |
| Jazz Pharmaceuticals INC. | $13.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.